Adam Bellack is Co-Head (Americas) of our Life Sciences Transactions team. Adam is a licensing and commercial lawyer with deep pharma, biotech, and health care industry knowledge focused on transactional matters for life sciences companies. For the last three years, Adam has been recognized by Law360 as a Life Sciences "Rising Star" and one of the nation's top Life Sciences lawyers under 40.

Adam's clients are engaged in all aspects of the health care industry including pharmaceutical, biotech, and medical device companies; universities; academic medical centers; and health systems.

Adam advises on a broad range of transactional matters, including license and collaboration agreements, product options and divestitures, affiliations, joint ventures, and other strategic transactions. Adam also handles commercial arrangements and complex contracting matters for life sciences companies, including manufacturing, supply, distribution, promotion, development, and clinical trial agreements.

In addition to advising on transactional matters, Adam provides corporate and compliance advice to private companies, institutions, and their boards.

Before joining Hogan Lovells, Adam worked as an associate for another large, international law firm in Washington, D.C. Previously, he worked as a law clerk for The Honorable Justice Robert L. Eastaugh of the Alaska Supreme Court.

Awards and recognitions

2017

Top Rated, Mergers & Acquisitions
Super Lawyers

2017

Top Rated, Health Care
Super Lawyers

2017

Top Rated, Technology Transactions
Super Lawyers

2017

Top Rated, Business/Corporate
Super Lawyers

2017

Rising Star
Super Lawyers

2015-2017

Rising Star - Life Sciences
Law360

2016

DC’s Top 40 Lawyers Under 40
Legal Bisnow Trending 40

Education and admissions

Education

J.D., The University of Chicago Law School, 2002

A.B., Harvard University, magna cum laude, 1999

Bar admissions and qualifications

District of Columbia

Representative experience

Representation of Sanofi in its US$2.2bn global collaboration with Regeneron to develop new antibody-based immuno-oncology treatments.

Representation of NextCure in connection with its formation, US$67m Series A financing and license and research agreements with Yale University.

Representation of TESARO in its license and collaboration agreement with Janssen Biotech involving Niraparib for the treatment of prostate cancer.

Representation of Novartis in its landmark portfolio transformation transactions with GlaxoSmithKline and Eli Lilly valued at more than US$23bn.

Representing a global technology company in licensing its glucose monitoring "smart lens" technology, and in the creation of a JV to develop next generation surgical robots.

Representation of Merck in the formation of a joint venture to detect and prevent the online sale of counterfeit pharmaceuticals.

Representation of Merck in the sale of its biomanufacturing network to Fujifilm.

Representation of Amplimmune in connection with product option and license agreements with GlaxoSmithKline and Daiichi Sankyo.

Representation of Amplimmune in connection with its sale to AstraZeneca and MedImmune.

Representation of the University of Pennsylvania in its collaboration and license agreement with Novartis regarding novel CAR T-cell immunotherapies.

Representation of TESARO in equity financing transactions, its initial public offering, licensing transactions and commercial arrangements.

Representation of New Enterprise Associates and Kleiner Perkins Caufield & Byers in equity investments in healthcare-related portfolio companies.

Representation of Altoona Regional Health System and Hamot Medical Center in connection with affiliations with University of Pittsburgh Medical Center.

Representation of The University of Colorado in connection with the formation of University of Colorado Health.

Representation of SUNY in connection with the acquisition by SUNY Upstate Medical Center of Community General Hospital in Syracuse.

Representation of SUNY in the acquisition by SUNY Downstate Medical Center of Long Island College Hospital in Brooklyn.

Latest thinking and events

Loading data